Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Beneficial Ownership Report · SCHEDULE 13G

Werewolf Therapeutics, Inc.

HOWLNASDAQEQUITYCurrent

Beneficial Ownership Report

Filed Sep 21, 2026Accepted Sep 21, 2026, 11:11 AM EDTFiling CIK 1732748Accession 0001732748-26-000003
Share

Structured filing — SCHEDULE 13G

primary_doc.xml

Open full document ↗

Subject company

Company
Werewolf Therapeutics, Inc.
Company CIK
0001785530
Street
303 WYMAN STREET
Street (continued)
SUITE 300
City
WALTHAM
State / country code
MA
Postal code
02451

Statement details

Security class
Common stock 0,0001$ per share
Event date
09/18/2026
Rule designation
Rule 13d-1(d)

Reporting person 1

Name
MOLL PETER
Citizenship / organization
2M
Reporting person type
OO
Aggregate amount owned
2,537,138.00
Percent of class
5.2
Sole voting power
2,537,138.00
Shared voting power
0.00
Sole dispositive power
2,537,138.00
Shared dispositive power
0.00
Comments
Private Investor

Item 1

Issuer

Werewolf Therapeutics, Inc.

Principal executive office address

303 WYMAN STREET, SUITE 300, WALTHAM, MASSACHUSETTS, 02451

Item 2

Citizenship

German

Filing person

Peter Moll

Principal business or residence address

Degelestr. 3, 01324 Dresden, Germany

Item 3

Not applicable indication

Y

Item 4

Percent of class

5.2

Amount beneficially owned

2537138

Sole voting power

2537138

Shared voting power

5.2

Sole dispositive power

2537138

Shared dispositive power

0

Item 5

Not applicable indication

Y

Ownership of 5% or less

N

Item 6

Not applicable indication

Y

Item 7

Not applicable indication

Y

Item 8

Not applicable indication

Y

Item 9

Not applicable indication

Y

Item 10

Not applicable indication

N

Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

Signature comments

Peter Moll

Signature 1

Reporting person
MOLL PETER
Signed
PeterMoll
Title
Owner
Date
09/21/2026

Company context

Werewolf Therapeutics, Inc., is an innovative biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer and other immune-mediated conditions. The Company has designed conditionally activated INDUKINETM molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Werewolf’s INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s clinical stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors. To learn more visit www.werewolftx.com.

Current securities

Recent company filings

  1. SCHEDULE 13G - filed by BALYASNY ASSET MANAGEMENT L.P. regarding Werewolf Therapeutics, Inc.Nov 16, 2026
  2. 10-Q filingNov 13, 2026
  3. EFFECT filingNov 12, 2026
  4. 424B3 filingNov 12, 2026
  5. S-4/A filingNov 10, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.